Celyad SA (NASDAQ: CYAD) and TG Therapeutics (NASDAQ:TGTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for Celyad SA and TG Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celyad SA 0 0 1 0 3.00
TG Therapeutics 0 0 10 0 3.00

Celyad SA presently has a consensus target price of $49.00, suggesting a potential downside of 8.07%. TG Therapeutics has a consensus target price of $26.89, suggesting a potential upside of 130.81%. Given TG Therapeutics’ higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Celyad SA.

Volatility and Risk

Celyad SA has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Insider & Institutional Ownership

4.1% of Celyad SA shares are held by institutional investors. Comparatively, 49.9% of TG Therapeutics shares are held by institutional investors. 16.7% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Celyad SA and TG Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celyad SA N/A N/A N/A
TG Therapeutics -68,806.59% -154.02% -117.88%

Earnings & Valuation

This table compares Celyad SA and TG Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Celyad SA $13.71 million 36.87 -$23.19 million N/A N/A
TG Therapeutics $152,381.00 4,763.79 -$104.96 million ($1.95) -5.97

Celyad SA has higher revenue and earnings than TG Therapeutics.


Celyad SA beats TG Therapeutics on 6 of the 11 factors compared between the two stocks.

About Celyad SA

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

About TG Therapeutics

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Receive News & Stock Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related stocks with our FREE daily email newsletter.